| Outcomes |
N |
Summary estimate |
95% CI |
Current clinical control
Change from baseline in asthma control days |
214 |
MD = -0.07 |
-0.14, -0.01 |
| Proportion of asthma control days |
330 |
MD = -0.09 |
-0.14, -0.04 |
| Change from baseline use of β2-agonists (puffs/day) |
442 |
MD = 0.12 |
0.00, 0.23 |
| Cumulative doses of rescue albuterol (μg) |
214 |
MD = 51.47 |
11.36, 91.57 |
| Change from baseline morning PEFR (%) |
350 |
MD = -2.56 |
-4.49, -0.63 |
| Change from baseline in FEV1 (%) |
365 |
MD = -0.49 |
-5.82, 4.84 |
| Change from baseline in exhaled NO (parts per billion) |
214 |
MD = 16.80 |
11.95, 21.64 |
| Change from baseline in the proportion of symptom-free days |
984 |
SMD = -0.15 |
-0.28, -0.03 |
| Change from baseline in daytime symptom scores |
591 |
SMD = 0.13 |
-0.04, 0.29 |
| Change from baseline in night-time awakenings |
448 |
MD = -0.03 |
-0.08, 0.02 |
| Change from baseline in quality of life |
389 |
SMD = -0.16 |
-0.36, 0.04 |
Future risk
Time to first exacerbation requiring oral corticosteroids |
492 |
HR = 0.88 |
0.55, 1.40 |
| Patients with ≥1 exacerbation requiring an acute care visit |
1055 |
RR = 1.08 |
0.90, 1.30 |
| Patients with ≥1 exacerbation requiring a hospital admission |
1204 |
RR = 0.85 |
0.29, 2.49 |
| Number of exacerbations requiring ED visits |
264 |
RR = 0.69 |
0.14, 3.44 |
| Overall withdrawals |
1210 |
RR = 1.04 |
0.79, 1.37 |
| Withdrawals due to poor asthma control |
1063 |
RR = 1.60 |
0.56, 4.52 |
| Withdrawals due to adverse effects |
1063 |
RR = 0.78 |
0.21, 2.92 |
| Overall adverse effects |
726 |
RR = 1.00 |
0.89, 1.13 |
| Nausea |
393 |
RR = 1.15 |
0.56, 2.35 |
| Upper respiratory tract infection |
393 |
RR = 1.14 |
0.96, 1.35 |
| Change in height (cm) |
532 |
MD = 0.41 |
0.13, 0.69 |
MD: Mean Difference; SMD: Standard Mean Difference; HR: Hazard Ratio; RR: Risk Ratio; PEFR: Peak Expiratory Flow Rate; FEV1: Forced Expired Volume In One
Second; NO: Nitric Oxide. |
